Literature DB >> 17981480

Inhibition of canine telomerase in vitro and in vivo using RNAi: further development of a natural canine model for telomerase-based cancer therapies.

J R Lund1, M Paoloni, I Kurzman, M Padilla, D J Argyle.   

Abstract

Despite advances in cancer therapy, cancer related morbidity and mortality among humans and companion animals remains high, and there is a clear need to develop novel targeted therapies. Expression of the enzyme telomerase has emerged as a central unifying mechanism underlying the immortal phenotype of canine cancer cells and has thus become a candidate for targeted molecular therapies. In this study, the value of telomerase inhibition to target telomerase expressing cancer cells was explored using the novel mechanism of RNA interference (RNAi). Using a Lentiviral expression construct, targeting the RNA component of canine telomerase was effective at inhibiting telomerase in vitro and tumour growth in vivo, but possible resistance mechanisms are highlighted. As canine telomerase biology is more closely related to human telomerase biology than the murine system, it is proposed that this study highlights the value of natural canine models to study anti-telomerase therapies for human patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981480     DOI: 10.1016/j.tvjl.2007.09.015

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  2 in total

1.  A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.

Authors:  Daniela Peruzzi; Alessandra Gavazza; Giuseppe Mesiti; George Lubas; Elisa Scarselli; Antonella Conforti; Claus Bendtsen; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

Review 2.  Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.

Authors:  Song He; Dechun Zhang; Fang Cheng; Fanghong Gong; Yanan Guo
Journal:  Mol Biol Rep       Date:  2009-01-01       Impact factor: 2.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.